Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9716632 | 1.00 | CYP3A4 (0.50) | CYP3A4LMNATRPM8ALDH1A1GLA | |
| SCHEMBL9716636 | 1.00 | CYP3A4 (0.50) | CYP3A4LMNATRPM8ALDH1A1GLA | |
| SCHEMBL10591288 | 0.84 | CYP3A4 (0.64) | CYP3A4LMNATRPM8ALDH1A1GLA | |
| SCHEMBL8171082 | 0.84 | CYP3A4 (0.46) | CYP3A4LMNATRPM8ALDH1A1GLA | |
| SCHEMBL20314812 | 0.83 | TRPM8 (0.46) | CYP3A4TRPM8ALDH1A1GLATSHR | |
| SCHEMBL9405499 | 0.83 | TRPM8 (0.46) | CYP3A4TRPM8ALDH1A1GLATSHR | |
| SCHEMBL10220933 | 0.81 | TRPM8 (0.69) | LMNATRPM8ALDH1A1GLACYP2C9 | |
| SCHEMBL20314815 | 0.79 | TRPM8 (0.43) | TRPM8ALDH1A1GLATSHRMEN1 | |
| SCHEMBL2992708 | 0.79 | GSTO1 (0.54) | CYP3A4TRPM8ALDH1A1GLATSHR | |
| SCHEMBL690247 | 0.76 | ALDH1A1 (0.53) | CYP3A4ALDH1A1GLATSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179232-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-06-28 | — | — | US | disclosed |
| US-20180179232-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179232-A1 | BORONIC ACID DERIVATIVES | BCL9, BCL9L, BCL6 | CYP3A4 4165/4885LMNA 1855/4885TRPM8 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.